Initiation of dosing in our Phase 1b clinical trial represents an important step in the clinical development of GT-02287 and in Gain’s mission to deliver a disease-modifying therapy to people with ...

Interim Analysis Expected End of 2Q 2025 BETHESDA, MD / ACCESS Newswire / March 14, 2025 / Gain Therapeutics, Inc. (Nasdaq:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company lead ...

Gain Therapeutics (GANX) announced the dosing of the first participant with Parkinson’s disease in its Phase 1b clinical trial of GT-02287, the ...

Saelig Company, Inc. has introduced the Siglent SSG6082A-V Vector Signal Generator, which provides an output frequency range from 9 kHz to 8 GHz, with AM, FM, and PM analog modulation as well as pulse ...

Hudson Therapeutics, the U.S. subsidiary of Shaperon, announced today that Shaperon will commence the Phase 2b Part 2 of its ...

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...

Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.

A new study published in Engineering offers insights into nonlinear meta-devices. Conducted by researchers from the City ...

“Extending the first phase of the deal in the format that Israel wants is unacceptable to the organization,” Hamas spokesman Hazem Qassem told Al-Araby TV. Qassem said there were no talks over ...

CAIRO (AP) — Israel’s government said early Sunday it supports a proposal to extend the first phase of the ceasefire in Gaza through Ramadan and Passover, though Hamas has insisted on ...

Talks on the second phase of the ceasefire between Israel and Hamas have made no progress so far and it is unclear whether they would resume on Saturday, a senior Hamas official said.